Philips enrolls first patient in U.S. clinical trial for innovative integrated single-device to treat peripheral artery disease

  • With a unique world-first ability to perform laser atherectomy and laser-based intravascular lithotripsy using a single device, Philips takes a major step forward in the treatment of peripheral artery disease (PAD)
  • Cardiovascular Institute of the South successfully treats first patient in the U.S. using Philips’ innovative laser system, marking a milestone in advancing personalized care for PAD patients

Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced enrollment of the first patient in the U.S. THOR IDE clinical trial, which will study an innovative combined laser atherectomy and intravascular lithotripsy catheter developed by Philips, that integrates two critical PAD treatments into a single device. Procedures that previously required the use of two different devices can now be performed in a single procedure using a single device, simplifying workflows and procedures and potentially reducing the risk and improving outcomes for patients who might otherwise face multiple complex interventions.

The Cardiovascular Institute of the South in Louisiana recently completed the first case using the new laser catheter. The care team there successfully treated a 78-year-old male with peripheral vascular disease using the Philips device.

“Developing and driving clinical evidence is crucial to improving care and guiding the adoption of new technologies like the Philips laser atherectomy and lithotripsy system,” said Drs. Craig Walker and McCall Walker of Cardiovascular Institute of the South in Louisiana. “This trial will provide essential data to demonstrate how this combined approach can optimize procedural efficiency and patient outcomes in treating challenging calcified lesions.”

This ground-breaking first procedure not only marks the launch of the THOR IDE trial. It also showcases how this innovative new technology, which resulted from Philips’ powerful in-house development capabilities, can ease the patient experience by streamlining complex interventions into a single procedure, potentially reducing the need for multiple interventions and hospital visits.

The goal of this pivotal study is to evaluate the safety and efficacy of using this unique laser device — a first-of-its-kind solution that integrates laser atherectomy and intravascular lithotripsy in a single device to treat complex, calcified lesions in a single procedure for patients with peripheral artery disease (PAD), restoring blood flow to their legs.

Significantly simplifying the treatment workflow
PAD is a common and serious condition that affects millions of people worldwide, particularly older adults and those with diabetes or high cholesterol. It leads to reduced blood flow to the limbs, often resulting in severe pain, ulcers, and, in extreme cases, limb amputation [1]. Patients with calcified lesions represent a particularly challenging group, as traditional treatment options often involve multiple steps and devices, increasing procedural complexity and risk.

The Philips laser catheter integrates two critical PAD treatments into a single device, significantly simplifying the treatment workflow – atherectomy to remove atherosclerotic plaque from the internal surface of an artery, and intravascular lithotripsy to modify calcium deposits within the artery or disrupt calcium deposits in the artery wall. The unique and highly innovative feature of the Philips catheter is that both the atherectomy and lithotripsy are laser-driven. Compared to conventional intravascular lithotripsy devices, which require the use of a separate ultrasound catheter to create calcium-disrupting sonic shockwaves, the Philips device uses a pulsed laser to instantly vaporize fluid within the blood vessel to create bubbles that expand and then rapidly collapse, generating the required sonic waves as they do so. 

Prospective, single-arm, multicenter study
The prospective, single-arm, multicenter study will enroll up to 155 patients at up to 30 sites in the U.S. Conducted under an Investigational Device Exemption (IDE) from the U.S. Food and Drug Administration (FDA), it will assess the system's safety and effectiveness in achieving procedural success with a low rate of complications.

The study’s primary endpoints include freedom from major adverse events (MAEs) such as mortality, unplanned amputations, and clinically driven target lesion revascularization (CD-TLR) within 30 days (about four and a half weeks) of the procedure, as well as achieving less than or equal to 50% residual stenosis post-procedure. Patients will be followed for 12 months.

“This innovative approach to vessel preparation could improve patient outcomes while minimizing the need for multiple therapies and interventions. That makes this an exciting innovation milestone as we enroll the first patient in this important U.S. clinical trial,” said Dr. Genovese, MD, vascular surgeon and co-principal investigator of the THOR* trial at the Penn Advanced Limb Preservation, Hospital of the University of Pennsylvania. “Integrating atherectomy and intravascular lithotripsy into a single device has the potential to revolutionize the treatment of patients with complex femoropopliteal lesions associated with moderate to severe calcifications.”

Stacy Beske, Business Leader, Philips Image Guided Therapy Devices, added: “A result of Philips’ extensive in-house innovation and development capabilities, our combined laser atherectomy and intravascular lithotripsy device reflects our commitment to providing physicians with the tools they need to tackle complex vascular challenges more efficiently and effectively, potentially transforming treatment paradigms for peripheral artery disease.  Philips is dedicated to clinically validating its innovations through rigorous trials and does so in collaboration with strong clinical partners.”

The Philips laser atherectomy and intravascular lithotripsy system is currently investigational and not yet commercially available anywhere in the world, including the United States.

[1] Peripheral artery disease (PAD) - Symptoms and causes - Mayo Clinic

Attachments

  • THOR Integrated Device
  • THOR First Patient Milestone Release_FINAL


Philips enrolls first patient in U.S. clinical trial for innovative integrated single-device to treat peripheral artery disease

THỦ THUẬT HAY

Hướng dẫn cách để lấy lại tại khoản Facebook nếu có bị hack

Để khắc phục vấn đề này, Facebook đã có hướng dẫn cụ thể về các thao tác người dùng cần làm trong trường hợp tài khoản bị chiếm đoạt. Cụ thể, nếu người dùng không có quyền truy cập vào tài khoản Facebook của mình, có

Vài thủ thuật nhỏ giúp Xperia XA1 Plus dùng sướng và ngon hơn

Một điểm mà Sony làm mình buồn ơi là buồn đó là mặc dù điện thoại của họ có màn hình to nhưng vẫn cứ nhất định để độ phân giải hiển thị nhỏ (mặt giận dữ).

Hyperion Launcher - một launcher hoàn toàn mới từ nhà phát triển ứng dụng Substratum

Sau thành công của Substratum, các nhà phát triển Projekt Development Team đã bất ngờ chuyển sang một dự án hoàn toàn mới. Họ đang nghiên cứu và phát triển một launcher có khả năng tùy biến cao được gọi là Hyperion,

Hướng dẫn khôi phục toàn bộ tin nhắn đã xóa trên iPhone một cách dễ dàng

Việc sử dụng iCloud để khôi phục tin nhắn đã xóa trước đó sẽ dễ dàng khi bạn từng lưu trữ dữ liệu từ iPhone sang iCloud hoặc Itunes.

4 cách để sửa chữa ổ cứng bị unallocated trong Windows 10/8/7

Dưới đây là bốn phương pháp hiệu quả để sửa chữa ổ cứng bị unallocated (chưa được phân bổ dung lượng) trong Windows 10/8/7. Vì vậy, bạn có thể dễ dàng sửa chữa ổ cứng nếu gặp vấn đề này.

ĐÁNH GIÁ NHANH

Đánh giá Redmi Note 4: Một thiết bị đậm chất Xiaomi

Sau khi Xiaomi chính thức bước chân vào Việt Nam, chiếc Redmi Note 4 đang là chiếc smartphone được nhiều người chú ý ở phân khúc dưới 5 triệu. Mời...

Đánh giá nhanh tai nghe AKG kèm Galaxy S8: Vẫn chưa như mong đợi

Trong sự kiện ra mắt vừa qua, ngoài tâm điểm là chiếc Galaxy S8 với vẻ ngoài mê hoặc, người dùng có thể sẽ quan tâm hơn đến phụ kiện kèm theo của...

Trải nghiệm và đánh giá nhanh Camera Galaxy A6+

Để có thể đưa ra nhận định tương đối sâu sát về cụm camera trước lẫn sau trên Galaxy A6/A6+, mình đã chụp kết hợp nhiều điều kiện ánh sáng khác nhau trong khi lang thang đường phố Sài Gòn, từ đủ sáng, chênh sáng, ánh